Evidence map›Paper›PMID 34823326›Full record

ArticleSingapore medical journal2024

Ulcerative colitis: STRIDE-ing beyond symptoms with new standards.

Shu Wen Tay, Kevin Kim Jun Teh, Tiing-Leong Ang, Malcolm Tan

Abstract read
In one paragraph

Article in Singapore medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shu Wen TayDepartment of Gastroenterology and Hepatology, Changi General Hospital, Singapore.ORCID 0000-0001-6390-4101
Kevin Kim Jun TehDepartment of Gastroenterology and Hepatology, Changi General Hospital, Singapore.ORCID 0000-0001-8832-9561
Tiing-Leong AngDepartment of Gastroenterology and Hepatology, Changi General Hospital, Singapore.ORCID 0000-0001-9993-8549
Malcolm TanMedicine ACP, SingHealth Duke-NUS Academic Medical Centre, Singapore.ORCID 0000-0001-7316-3888

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The landscape of ulcerative colitis has changed in the last two decades. Advancements in pharmacotherapeutics have heralded the introduction of new treatment options, with many agents in development. Better clinical outcomes are seen with tighter disease control, made possible with greater understanding of inflammatory pathways and their blockade with drugs. There has been a resultant shift in treatment targets, beyond symptoms to endoscopic and histological healing. Controlling the burden of disease activity also lowers the risk of developing colorectal cancer. Colorectal cancer screening now requires the use of dye-based agents and high-definition colonoscopy to improve the detection of colonic neoplasms.

Indexed as

Colitis, UlcerativeColonic NeoplasmsColorectal NeoplasmsColonoscopyHumansWound Healing

Identifiers

PMID34823326
PMCPMC10942141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.